RARα agonists(Retinoic acid receptor alpha agonists), RARβ2 agonists(Retinoic acid receptor beta agonists), RARγ agonists(Retinoic acid receptor gamma agonists)

Therapeutic Areas

NeoplasmsImmune System DiseasesInfectious Diseases+ [2]

Active Indication

AIDS-related Kaposi Sarcoma

Inactive Indication

Acute Promyelocytic LeukemiaBreast CancerBronchial Diseases+ [8]

Originator Organization

Eisai Co., Ltd.

Active Organization

Concordia Pharmaceuticals, Inc.

Inactive Organization

Eisai GmbH

Ligand Pharmaceuticals, Inc.

Drug Highest PhaseApproved

First Approval Date

US (02 Feb 1999),

AIDS-related Kaposi Sarcoma

RegulationOrphan Drug (US)

Structure

Molecular FormulaC20H28O2

InChIKeySHGAZHPCJJPHSC-ZVCIMWCZSA-N

CAS Registry5300-03-8

Clinical Trials associated with Alitretinoin

NCT06172296 / RecruitingPhase 3IIT

A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma

This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.

Start Date19 Apr 2024

Sponsor / Collaborator

National Cancer Institute

NCT05384821 / RecruitingPhase 1/2

Phase 1-2 Trial Evaluating Metronomic Chemotherapy in Patients With a Relapsed or Refractory Wilms Tumor

This is a multicenter, interventional, non-randomized study among patients with a relapsed or refractory Wilms tumor. The study will aim to assess efficacy of metronomic chemotherapy, in terms of disease control after two cycles of metronomic chemotherapy.

Start Date14 Sep 2022

Sponsor / Collaborator

Centre Oscar Lambret

NCT05077813 / Unknown statusPhase 2IIT

Utilizing the Crosstalk Among Chicoric Acid, 13-Cis Retinoic Acid(Aerosolized), Minocycline and Vitamin D as a Potent Quadrate Therapy for Treating Patients With Multidrug-resistant TB and Patient With Both Multidrug-resistant TB and COVID-19

Utilizing the Crosstalk Among Chicoric Acid, 13-Cis Retinoic Acid(Aerosolized), Minocycline and Vitamin D as a Potent Quadrate Therapy for treating patients with Multidrug-resistant TB and patient with both Multidrug-resistant TB and COVID-19 . A double-edged sword Clinical Study
I)Part of Tuberculosis
Tuberculosis (TB) is a major infectious disease killer globally. It affected 10 million and killed 1.4 million people in 2019 alone. The predicted impact of the COVID-19 pandemic is an additional 190,000 TB deaths in 2020, and it is expected in the next 5 y that there will be up to a 20% increase in the global TB disease burden , stressing the critical need for new safe and effective drugs against Mycobacterium tuberculosis (Mtb). In addition, controlling multidrug-resistant TB (MDR-TB) presents a huge public health challenge . New drug discovery could require several years with no guarantee but repurposing established may be useful to treat patients with tuberculosis . Here we demonstrate that we could utilize the crosstalk among Chicoric Acid, 13-Cis Retinoic Acid, Minocycline , and vitamin D as a novel quadrate therapy against TB.Drug-resistant tuberculosis represents a global emergency, requiring new drugs. Recently Minocycline was found to be highly potent in laboratory strains of Mycobacterium TB, and 30 drug-sensitive and multidrug/extensively drug-resistant clinical strains were susceptible to clinically attainable dosages. The lung concentration-time profiles of a 7 mg/kg/day human-equivalent minocycline dosage yielded bacterial kill rates comparable to first-line antituberculosis drugs. Extracellular bacilli were destroyed directly by minocycline. Minocycline also killed intracellular bacilli indirectly through granzyme A-driven apoptosis. Furthermore, minocycline showed dose-dependent antiinflammatory effect, suggesting that it may protect tuberculosis patients against immunopathology. A study showed that M. tuberculosis induced the expression of indoleamine 2,3-dioxygenase (IDO), an enzyme involved in tryptophan catabolism, in macrophages and in the lungs of animals (mice and macaque) with active disease. In a macaque model of inhalation TB, suppression of IDO activity reduced bacterial burden, pathology, and clinical signs of TB disease, leading to increased host survival. This increased protection was accompanied by increased lung T cell proliferation, induction of inducible bronchus-associated lymphoid tissue and correlates of bacterial killing . A recent study showed that Minocycline-induced significantly inhibition of IDO expression. But Minocycline-induced inhibition of IDO expression is retinoid-dependent. The combined treatment with minocycline and retinol, however, resulted in a striking, statistically significant decrease in IDO. Co-treatment with minocycline and retinol again resulted in decreased TNF-α and IL-6 levels. A study showed that IL-6 inhibits IFN-γ induced autophagy in Mycobacterium (TB) H37Rv infected macrophages. As well as neutralization of endogenous IL-6 by anti-IL-6 antibody significantly enhances the IFN-γ mediated killing of the intracellular bacteria. Minocycline's anti-inflammatory effects are mediated through RAR signaling. Therefore, The combined treatment with minocycline and retinol is expected to effectively inhibit (TB) and its inflammatory complication, Fortunately, Retinoic Acid significantly inhibits the in vivo growth of M. tuberculosis and the development of tuberculosis. In addition to, 13-Cis RA and Chicoric Acid ( CA ) enhanced the cell surface expression of HLA-DR and CD14 molecules on U937 macrophages and prevented the growth of Mtb within macrophages. Moreover, 13-cis RA and CA, have increased NO generation compared to untreated control macrophages, significantly . Both drugs have a significant inhibitory effect on Mtb growth but CA at the highest concentration was more potent than 13-cis RA . Therefore we will use retinoic acid to induce the effect of Minocycline as well as its ability to inhibit tuberculosis in combination with CA .Recent data showed that Vitamin D support innate immune responses to Mycobacterium TB and Low vitamin D levels were associated with a 5-fold increased risk for progression to tuberculosis. Deficiency of vitamin D has long been implicated in activation of (TB) . Serum vitamin D in TB patients are lower than in healthy controls . Vitamin D has been found to speed up the clearance of (TB) bacteria from the lungs of people with multi-drug resistant TB, according to a study of 1,850 patients. It was showed that Vitamin D receptor (VDR) must form a heterodimer complex with retinoid X receptor (RXR) to regulate gene transcription. Retinol plays a crucial role in lung development and signaling the vitamin D pathway. 9-cis-retinoic acid, an active vitamin A metabolite and the ligand of RXR, assists VDR signaling and suppresses the degradation of circulating vitamin D.

Start Date01 Dec 2021

Sponsor / Collaborator

Kafrelsheikh University

100 Clinical Results associated with Alitretinoin

100 Translational Medicine associated with Alitretinoin

100 Patents (Medical) associated with Alitretinoin

2,372

Literatures (Medical) associated with Alitretinoin

05 Jul 2106·Oncotarget

Phospholipid scramblase 1 as a critical node at the crossroad between autophagy and apoptosis in mantle cell lymphoma

Article

Author: Dolcetti, Riccardo ; Col, Jessica Dal ; Inghirami, Giorgio ; Faè, Damiana A. ; Ponzoni, Maurilio ; Montico, Barbara ; Mastorci, Katy ; Sigalotti, Luca

Mantle cell lymphoma (MCL) is an aggressive haematological malignancy in which the response to therapy can be limited by aberrantly activated molecular and cellular pathways, among which autophagy was recently listed. Our study shows that the 9-cis-retinoic acid (RA)/Interferon(IFN)-α combination induces protective autophagy in MCL cell lines and primary cultures reducing the extent of drug-induced apoptosis. The treatment significantly up-regulates phospholipid scramblase 1 (PLSCR1), a protein which bi-directionally flips lipids across membranes. In particular, RA/IFN-α combination concomitantly increases PLSCR1 transcription and controls PLSCR1 protein levels via lysosomal degradation. Herein we describe a new function for PLSCR1 as negative regulator of autophagy. Indeed, PLSCR1 overexpression reduced MCL cell susceptibility to autophagy induced by RA/IFN-α, serum deprivation or mTOR pharmacological inhibition. Moreover, PLSCR1 can bind the ATG12/ATG5 complex preventing ATG16L1 recruitment and its full activation, as indicated by co-immunoprecipitation experiments. The combination of doxorubicin or bortezomib with RA/IFN-α strengthened PLSCR1 up-regulation and enhanced apoptosis, as a likely consequence of the blockade of RA/IFN-α-induced autophagy. Immunohistochemical analysis of 32 MCL biopsies revealed heterogeneous expression of PLSCR1 and suggests its possible implication in the response to anticancer therapies, especially to drugs promoting protective autophagy.

01 Feb 2024·Current molecular medicine

Intracellular Ellagic Acid Derived from Goat Urine DMSO Fraction (GUDF) Predicted as an Inhibitor of c-Raf Kinase

Article

Author: Nandangiri, Rasika ; Choudhary, Sumitra ; Raj, Ajay Kumar ; Lokhande, Kiran Bharat ; Prasad, Tanay Kondapally ; Sharma, Nilesh Kumar ; Pal, Jayanta Kumar

Background::

Dietary chemicals and their gut-metabolized products are explored for their anti-proliferative and pro-cell death effects. Dietary and metabolized chemicals are different from ruminants such as goats over humans.

Methods::

Loss of cell viability and induction of death due to goat urine DMSO fraction (GUDF) derived chemicals were assessed by routine in vitro assays upon MCF-7 breast cancer cells. Intracellular metabolite profiling of MCF-7 cells treated with goat urine DMSO fraction (GUDF) was performed using an in-house designed vertical tube gel electrophoresis (VTGE) assisted methodology, followed by LC-HRMS. Next, identified intracellular dietary chemicals such as ellagic acid were evaluated for their inhibitory effects against transducers of the c-Raf signaling pathway employing molecular docking and molecular dynamics (MD) simulation.

Results::

GUDF treatment upon MCF-7 cells displayed significant loss of cell viability and induction of cell death. A set of dietary and metabolized chemicals in the intracellular compartment of MCF-7 cells, such as ellagic acid, 2-hydroxymyristic acid, artelinic acid, 10-amino-decanoic acid, nervonic acid, 2,4-dimethyl-2-eicosenoic acid, 2,3,4'- Trihydroxy,4-Methoxybenzophenone and 9-amino-nonanoic acid were identified. Among intracellular dietary chemicals, ellagic acid displayed a strong inhibitory affinity (-8.7 kcal/mol) against c-Raf kinase. The inhibitory potential of ellagic acid was found to be significantly comparable with a known c-Raf kinase inhibitor sorafenib with overlapping inhibitory site residues (ARG450, GLU425, TRP423, VA403).

Conclusion::

Intracellular dietary-derived chemicals such as ellagic acid are suggested for the induction of cell death in MCF-7 cells. Ellagic acid is predicted as an inhibitor of c-Raf kinase and could be explored as an anti-cancer drug.

01 Feb 2024·Cytotherapy

Phospholipid scramblase 1 is involved in immunogenic cell death and contributes to dendritic cell–based vaccine efficiency to elicit antitumor immune response in vitro

Article

Author: Steffan, Agostino ; Casolaro, Vincenzo ; Dal Col, Jessica ; Dolcetti, Riccardo ; Mastorci, Katy ; Lamberti, Maria Julia ; Giurato, Giorgio ; Montico, Barbara ; Nigro, Annunziata ; Ravo, Maria ; Martorelli, Debora

BACKGROUND AIMS:

Whole tumor cell lysates (TCLs) obtained from cancer cells previously killed by treatments able to promote immunogenic cell death (ICD) can be efficiently used as a source of tumor-associated antigens for the development of highly efficient dendritic cell (DC)-based vaccines. Herein, the potential role of the interferon (IFN)-inducible protein phospholipid scramblase 1 (PLSCR1) in influencing immunogenic features of dying cancer cells and in enhancing DC-based vaccine efficiency was investigated.

METHODS:

PLSCR1 expression was evaluated in different mantle-cell lymphoma (MCL) cell lines following ICD induction by 9-cis-retinoic acid (RA)/IFN-α combination, and commercial kinase inhibitor was used to identify the signaling pathway involved in its upregulation. A Mino cell line ectopically expressing PLSCR1 was generated to investigate the potential involvement of this protein in modulating ICD features. Whole TCLs obtained from Mino overexpressing PLSCR1 were used for DC loading, and loaded DCs were employed for generation of tumor antigen-specific cytotoxic T lymphocytes.

RESULTS:

The ICD inducer RA/IFN-α combination promoted PLSCR1 expression through STAT1 activation. PLSCR1 upregulation favored pro-apoptotic effects of RA/IFN-α treatment and enhanced the exposure of calreticulin on cell surface. Moreover, DCs loaded with TCLs obtained from Mino ectopically expressing PLSCR1 elicited in vitro greater T-cell-mediated antitumor responses compared with DCs loaded with TCLs derived from Mino infected with empty vector or the parental cell line. Conversely, PLSCR1 knock-down inhibited the stimulating activity of DCs loaded with RA/IFN-α-treated TCLs to elicit cyclin D1 peptide-specific cytotoxic T lymphocytes.

CONCLUSIONS:

Our results indicate that PLSCR1 improved ICD-associated calreticulin exposure induced by RA/IFN-α and was clearly involved in DC-based vaccine efficiency as well, suggesting a potential contribution in the control of pathways associated to DC activation, possibly including those involved in antigen uptake and concomitant antitumor immune response activation.

News (Medical) associated with Alitretinoin

03 May 2024

·www.fiercepharma.com

Leo Pharma prepares to come for the topical JAK market as Incyte's Opzelura cream launch cools off

None Watch out, Incyte. Leo Pharma and its JAK inhibitor cream delgocitinib are coming to disrupt the topical atopic dermatitis market, currently inhibited by Incyte’s approved Opzelura. With several positive studies in hand, including a recent phase 3 trial pitting the candidate against the current standard-of-care, Leo says its delgocitinib has growth driver potential. Now, the drugmaker will be “investing additional resources in accelerating the launch of this potential treatment to patients,” Leo said in its first quarter earnings release. The cream is currently under regulatory review in Europe. As for other markets including the U.S., Leo is “assessing ways” to bring the potential treatment to commercialization, it said. Delgocitinib has been marked in Japan by Japan Tobacco for four years now. Leo's evidence supporting the drug includes two phase 3 studies against a placebo cream and an open-label extension study proving its success in treating patients with moderate-to-severe chronic hand eczema. Most recently, delgocitinib went up against standard-of-care alitretinoin capsules, the only currently approved treatment for chronic hand eczema patients who do not respond to topical corticosteroids. In the DELTA FORCE study of 513 patients, Leo’s candidate proved a superior reduction in scoring on the Hand Eczema Severity Index at week 12 and week 24. It also trumped alitretinoin in two other secondary measures assessing treatment success and quality of life. “We are confident that with the DELTA FORCE study, delgocitinib cream may play a crucial role in expanding the options available for patients in this hard-to-treat condition,” chief development officer Kreesten Meldgaard Madsen said at the time. If the drug scores approval, it would compete with the only other marketed topical JAK inhibitor, Incyte’s Opzelura. That med is a cream version of the company’s popular JAK inhibitor Jakafi. Other than atopic dermatitis, Opzelura is also approved to treat vitiligo. Incyte is now moving to expand the Jakafi counterpart into pediatric atopic dermatitis use and expects to submit its bid for the indication this year along with “multiple data readouts,” head of R&D Pablo Cagnoni said on the company’s first-quarter earnings call. A pediatric nod would add some two million to three million eligible patients to the med’s reach, the company said. Opzelura and Jakafi brought Incyte to blockbuster fourth-quarter sales last year, reflecting what the company’s North America general manager Barry Flannelly called “one of the best recent dermatology launches” on Opzelura’s part following its 2021 approval. More recently over this year’s first quarter, sales for both Opzelura and Jakafi sank on a quarterly basis, missing analyst’s consensus. While Jakafi was impacted by higher inventory drawdown and Opzelura by Change Helathcare’s cyberattack, the explanations “still will not provide investors with data point to suggest there is upside to estimates in the near term,” analysts at William Blair wrote in a note to clients. Opzelura pulled first-quarter revenues of $86 million, dipping 21.5% from the fourth quarter.

Phase 3Drug ApprovalClinical Result

24 Jan 2024

·www.fiercepharma.com

Leo scores again in hand eczema with its JAK inhibitor cream

Danish skin condition specialist Leo Pharma is building a case for approval of its JAK inhibitor cream delgocitinib to treat chronic hand eczema. It’s been four years since Japan Tobacco snagged approval in its home country for its topical JAK inhibitor delgocitinib to treat atopic dermatitis. Slowly but surely, Denmark’s Leo Pharma—which gained the rights to develop and commercialize delgocitinib in the rest of the world a decade ago—is working toward its first green light for the topical cream. Two identical phase 3 trials against a placebo cream and an open-label extension study have demonstrated delgocitinib’s success in treating patients with moderate-to-severe chronic hand eczema (CHE). Now, a fourth phase 3 study, comparing delgocitinib to alitretinoin capsules, has provided Leo with more evidence of its value. Alitretinoin is the only treatment approved for CHE patients who do not respond to topical corticosteroids. In the DELTA FORCE study of 513 patients, delgocitinib was associated with a superior reduction in the Hand Eczema Severity Index (HECSI), a scoring system in which success is defined by a two-point improvement on the following scale: 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate) and 4 (severe). From baseline to week 12, which was the primary measure in the study, patients who received delgocitinib twice daily had better clearance scores than those who took a once-daily dose of alitretinoin. As a secondary measure, from baseline to week 24, delgocitinib also provided superior results to alitretinoin. Delgocitinib outperformed alitretinoin in two other secondary measures—the Investigator’s Global Assessment (IGA)-CHE treatment success and the Dermatology Life Quality Index (DLQI). Additionally, patients receiving delgocitinib experienced fewer adverse events than those receiving alitretinoin. The overall safety profile was consistent with what was observed in the previous three trials—DELTA 1, 2 and 3. “We are confident that with the DELTA FORCE study, delgocitinib cream may play a crucial role in expanding the options available for patients in this hard-to-treat condition,” Kreesten Meldgaard Madsen, Leo’s chief development officer, said in a release. Detailed results from DELTA FORCE will be provided for publication later, Leo said. The only other topical JAK inhibitor on the market is Incyte’s Opzelura, which was approved for mild-to-moderate cases of eczema in 2021. The treatment, which is the cream version of Incyte’s blockbuster Jakafi, and is off to a successful launch, generating sales of $80 million and $92 million in the second and third quarters of last year. Safety issues with JAK inhibitor creams are being closely monitored because oral treatments from the drug class—such as Pfizer’s Xeljanz, Eli Lilly’s Olumiant and AbbVie’s Rinvoq—now carry warnings about increased risk of heart attack and stroke.

Clinical ResultPhase 3Drug Approval

24 Jan 2024

·www.pmlive.com

LEO shares positive results for delgocitinib cream in head-to-head chronic hand eczema study

LEO Pharma has announced positive results from a head-to-head study of its investigational JAK-inhibitor cream, delgocitinib, in adults with severe chronic hand eczema (CHE). Hand eczema is the most common skin disorder of the hands and one of the most common types of eczema. In patients with hand eczema, the skin is generally dry, scaly and thickened, and the fingers can become swollen when the eczema is flaring. Other symptoms may include cracking, soreness, bleeding and, in some cases, blisters. CHE, which affects a substantial number of patients, is defined as hand eczema that lasts for more than three months or relapses twice or more within a year. Alitretinoin is currently the only treatment specifically approved to treat severe CHE in patients who do not respond to topical corticosteroids. The late-stage DELTA FORCE study has been comparing the efficacy and safety of twice-daily delgocitinib cream with once-daily alitretinoin capsules. The primary endpoint of the trial was met with delgocitinib cream demonstrating a superior reduction in Hand Eczema Severity Index (HECSI) score from baseline to week 12 compared to alitretinoin capsules. The candidate also demonstrated superiority to alitretinoin capsules in all key secondary outcome measures, including Investigator’s Global Assessment-CHE treatment success, a reduction in HECSI score from baseline to week 24, and a significant improvement in health-related quality of life. Additionally, patients receiving delgocitinib cream experienced a lower number of treatment-emergent adverse events compared to those receiving alitretinoin capsules, and no specific treatment-emergent safety concerns were identified for the candidate. Further data analyses will be conducted to determine any “additional potential” of delgocitinib cream in the treatment of adults with moderate-to-severe CHE, LEO said, adding that detailed results from the trial are planned to be submitted for scientific presentation and publication “at a later date”. Kreesten Meldgaard Madsen, chief development officer at LEO, said: “Currently, there is only one specific treatment option available for those living with severe CHE. “We are confident that with the DELTA FORCE study, delgocitinib cream may play a crucial role in expanding the options available for patients in this hard-to-treat condition.”

Clinical ResultDrug ApprovalPhase 3

100 Deals associated with Alitretinoin

External Link

KEGG	Wiki	ATC	Drug Bank
D02815	Alitretinoin	L01XX22 D11AH04	DB00523

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
AIDS-related Kaposi Sarcoma	US	Concordia Pharmaceuticals, Inc.	02 Feb 1999

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Promyelocytic Leukemia	Phase 3	US	Ligand Pharmaceuticals, Inc.	30 Jun 1999
Bronchial Diseases	Phase 2	US	Ligand Pharmaceuticals, Inc.	01 Jan 2001
Myelodysplastic Syndromes	Phase 2	US	Ligand Pharmaceuticals, Inc.	26 Mar 1998
Breast Cancer	Phase 2	US	Ligand Pharmaceuticals, Inc.	23 May 1997
Prostatic Cancer	Phase 2	US	Ligand Pharmaceuticals, Inc.	23 May 1997
Head and Neck Neoplasms	Phase 2	US	Ligand Pharmaceuticals, Inc.	27 Aug 1996
Ovarian Cancer	Phase 2	US	Ligand Pharmaceuticals, Inc.	27 Aug 1996
Squamous Cell Carcinoma	Phase 2	US	Ligand Pharmaceuticals, Inc.	27 Aug 1996
Kidney Neoplasms	Phase 2	CA	Ligand Pharmaceuticals, Inc.	23 May 1995
Non-Hodgkin Lymphoma	Phase 2	US	Ligand Pharmaceuticals, Inc.	23 May 1995

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00817063 (CTgov)	Phase 3	Chronic eczema	599	Placebo	wuosvabqfy(vwrpharflg) = fwgoybiyig jghxzklclx (uwuqhnitap, hoxbmpxwkt - qdlpxorzfq) View more	-	09 Nov 2017
NCT01245140 (CTgov)	Phase 2	Pustular psoriasis	33	placebo (Matching Placebo)	mekdefgfdm(trxtgojhsn) = jussneaucj iaodvckdmw (dwtwcvhtch, lwrxwrhora - obukrjltqg) View more	-	04 Apr 2017
NCT01245140 (CTgov)	Phase 2	Pustular psoriasis	33	Alitretinoin (Alitretinoin 30 mg)	mekdefgfdm(trxtgojhsn) = qnybjpcjmg iaodvckdmw (dwtwcvhtch, erjjykbunj - egmiweszsn) View more	-	04 Apr 2017
NCT00817063 (Pubmed)	Phase 3	Eczema	596	Alitretinoin 30 mg	ijkikxysyt(heuxbkezqi) = cdbumwmssi ocnushavpf (japjgbijji ) View more	Positive	01 Oct 2014
NCT00817063 (Pubmed)	Phase 3	Eczema	596	Placebo	bpyvthyrct(cddfiehsap) = unkssgcxwk hnyalvlmlc (uillxgzmek )	Positive	01 Oct 2014
NCT00609739 (CTgov)	Phase 1/2	Juvenile Myelomonocytic Leukemia	1	umbilical cord blood transplantation+methylprednisolone+Cis-Retinoic acid+cyclosporine+Filgrastim+mitoxantrone hydrochloride+methotrexate+Cytarabine	tiyuknmwjv(jrpufajqon) = cfwhwvvlra itvvdfbafw (uemuzdojqr, vlnefzeseq - fcvzievrky) View more	-	02 Mar 2012

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis